Literature DB >> 10644416

Effects of FTY720, a novel immunosuppressant, on experimental autoimmune uveoretinitis in rats.

S Kurose1, E Ikeda, M Tokiwa, N Hikita, M Mochizuki.   

Abstract

The immunosuppressive properties of FTY720, a novel immunosuppressant obtained by structural modification of ISP-I isolated from the fermentation broth of Isaria sinclairii, were studied in experimental autoimmune uveoretinitis (EAU) in rats. Lewis rats were immunized with S-antigen and treated with FTY720 (0. 03, 0.06, 0.1 mg kg(-1)day(-1)) or distilled water for 16 days after the immunization. FTY720 suppressed the incidence and intensity of EAU in a dose-dependent manner as demonstrated by clinical and histological examinations. The drug significantly suppressed the serum levels of antibodies to S-antigen and antigens-specific lymphocyte proliferation. The number of peripheral lymphocytes, but not neutrophils, was markedly reduced by FTY720 treatment. FTY720 also suppressed the intensity of EAU when it was given from the day of EAU onset. These results indicate that FTY720 has intense immunosuppressive effects on EAU in rats and may be a potential candidate for use in the treatment of patients with autoimmune uveitis. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10644416     DOI: 10.1006/exer.1999.0777

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  18 in total

Review 1.  Insights into the pharmacological relevance of lysophospholipid receptors.

Authors:  Tetsuji Mutoh; Richard Rivera; Jerold Chun
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

2.  Chronic sphingosine 1-phosphate 1 receptor activation attenuates early-stage diabetic nephropathy independent of lymphocytes.

Authors:  Alaa S Awad; Michael D Rouse; Konstantine Khutsishvili; Liping Huang; W Kline Bolton; Kevin R Lynch; Mark D Okusa
Journal:  Kidney Int       Date:  2011-02-02       Impact factor: 10.612

3.  Sphingosine 1-phosphate receptors are essential mediators of eyelid closure during embryonic development.

Authors:  Deron R Herr; Chang-Wook Lee; Wei Wang; Adam Ware; Richard Rivera; Jerold Chun
Journal:  J Biol Chem       Date:  2013-09-03       Impact factor: 5.157

Review 4.  Beyond the cherry-red spot: Ocular manifestations of sphingolipid-mediated neurodegenerative and inflammatory disorders.

Authors:  Hui Chen; Annie Y Chan; Donald U Stone; Nawajes A Mandal
Journal:  Surv Ophthalmol       Date:  2013-09-05       Impact factor: 6.048

Review 5.  [Treatment of posterior noninfectious uveitis : Current situation and future developments].

Authors:  U Pleyer; D Pohlmann; N Stübiger
Journal:  Ophthalmologe       Date:  2016-05       Impact factor: 1.059

Review 6.  Targeting the molecular and cellular interactions of the bone marrow niche in immunologic disease.

Authors:  Jaime M Brozowski; Matthew J Billard; Teresa K Tarrant
Journal:  Curr Allergy Asthma Rep       Date:  2014-02       Impact factor: 4.806

7.  [Intraocular inflammation in multiple sclerosis].

Authors:  N Stübiger; K Ruprecht; U Pleyer
Journal:  Ophthalmologe       Date:  2018-06       Impact factor: 1.059

8.  Acid Ceramidase Deficiency in Mice Leads to Severe Ocular Pathology and Visual Impairment.

Authors:  Fabian P S Yu; Benjamin S Sajdak; Jakub Sikora; Alexander E Salmon; Murtaza S Nagree; Jiří Gurka; Iris S Kassem; Daniel M Lipinski; Joseph Carroll; Jeffrey A Medin
Journal:  Am J Pathol       Date:  2018-11-23       Impact factor: 4.307

Review 9.  [Uveitis in multiple sclerosis : Overview and perspectives].

Authors:  A L Hildebrandt; F Mackensen
Journal:  Ophthalmologe       Date:  2014-08       Impact factor: 1.059

Review 10.  [FTY720 (Fingolimod) as a new therapeutic option for multiple sclerosis].

Authors:  J Klatt; H-P Hartung; R Hohlfeld
Journal:  Nervenarzt       Date:  2007-10       Impact factor: 1.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.